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Abstract
Background: Non-hereditary colorectal cancer (CRC) is a complex disorder resulting from the combination of genetic and
non-genetic factors. Genome–wide association studies (GWAS) are useful for identifying such genetic susceptibility factors.
However, the single loci so far associated with CRC only represent a fraction of the genetic risk for CRC development in the
general population. Therefore, many other genetic risk variants alone and in combination must still remain to be discovered.
The aim of this work was to search for genetic risk factors for CRC, by performing single-locus and two-locus GWAS in the
Spanish population.
Results: A total of 801 controls and 500 CRC cases were included in the discovery GWAS dataset. 77 single nucleotide
polymorphisms (SNP)s from single-locus and 243 SNPs from two-locus association analyses were selected for replication in
423 additional CRC cases and 1382 controls. In the meta-analysis, one SNP, rs3987 at 4q26, reached GWAS significant p-
value (p = 4.0261028), and one SNP pair, rs1100508 CG and rs8111948 AA, showed a trend for two-locus association
(p = 4.35610211). Additionally, our GWAS confirmed the previously reported association with CRC of five SNPs located at
3q36.2 (rs10936599), 8q24 (rs10505477), 8q24.21(rs6983267), 11q13.4 (rs3824999) and 14q22.2 (rs4444235).
Conclusions: Our GWAS for CRC patients from Spain confirmed some previously reported associations for CRC and yielded a
novel candidate risk SNP, located at 4q26. Epistasis analyses also yielded several novel candidate susceptibility pairs that
need to be validated in independent analyses.
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Introduction
Colorectal cancer (CRC) represents globally, in terms of
frequency, the third leading cause of cancer-related mortality,
and the second most frequent malignant disease in Europe [1]. A
minority of patients have a family history of CRC, suggesting some
hereditary contribution. Germ-line mutations have been identified
as the cause of inherited cancer risk in some of these CRC–prone
families. Overall, high penetrance mutations are estimated to
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account for less than 5% of CRC cases [2]. On the other hand, the
vast majority of patients with CRC have no clear evidence of
having inherited the disorder and are therefore classified as
‘‘sporadic’’ cancer.
Sporadic CRC is considered a complex disorder resulting from
the combination of genetic and non-genetic risk factors in concert
with somatic genetic and epigenetic alterations. The non-
Mendelian genetic risk factors are common low-risk variants
distributed throughout the genome. The Genome–wide associa-
tion studies (GWAS) approach is an useful tool for identifying such
variants [3]. Using this approach about 30 risk genetic variants
related to CRC susceptibility have been reported in the last years
[4–15]. In spite of this, the combined effect of these variants
altogether only represents a small proportion of the genetic risk for
CRC development in the general population [16]. This suggests
that many other risk genetic variants are yet to be discovered.
In general, GWAS have been insufficient to uncover all genes
involved in complex diseases and, most importantly, they have not
been very useful in isolating specific molecular pathways related to
the disorders under study [17]. One of the reasons could be that
single-locus approach is typically the only method applied to
GWAS datasets, and this does not take into account the multigenic
nature that underlies the etiology of complex diseases. Thus, new
analytical methods that would help to detect more powerful
genetic associations based on combination of markers have been
proposed by us and others [18–20]. Recently, the first two-locus
association study in CRC has been reported [21]. Additional
studies are clearly necessary for a more comprehensive under-
standing of the genetic complexity of CRC susceptibility in the
different human populations.
The aim of this work was to search for genetic risk factors for
CRC in the Spanish population, performing a new GWAS using
single-locus and two-locus genetic association analyses.
Results
Phase I. CRC-GWAS analysis
To identify CRC risk-associated SNPs, we designed a GWAS
(NXC-GWAS) comprising 801 controls and 500 cases from the
scarcely studied Spanish population (NXC-GWAS sample).
All of the SNPs were genotyped using the Affymetrix NSP I
250K chip. After quality control, 20 cases were discarded (4
discordant sex, 8 different ethnicity and 8 low sample call rate).
Finally, 480 cases and 801 controls were selected for association
analysis. Principal component analysis performed among this
sample did not reveal population admixture (Figure S1). Age at
recruitment was 58.069.1 years in cases and 51.968.8 years in
controls (mean 6 standard deviation). The corresponding number
(percentage) of female samples were 278 (57.9%), and 368
(45.9%), respectively. Among the 262264 SNPs that can be
genotyped with this chip, 83334 did not pass the quality controls
(52964 SNPs were discarded due to low minor allele frequency
(MAF), 2307 SNPs failed HWE, and 28333 had a significantly
different rate of missingness between case and control groups). A
total of 178,930 markers were finally selected for subsequent
association analyses. There was no overall inflation of the test
statistic (genomic inflation factor = 1.10) (see Figure S2), providing
reassurance that systematic confounding factors were unlikely.
Using Plink we carried out a single locus genetic association
analysis [22]. One genetic marker, rs10446758 in chromosome
4q31.23, reached the GWAS-significant p value (p = 1.7361028),
and other two markers, rs4887855 in chromosome 16q23.1 and
rs7171889 in chromosome 15q26.2, showed a trend for association
(p = 8.2761028 and p = 8.5361028, respectively) (figure 1) (Table
S1).
We also performed a two-locus analysis using the HFCC
software (see Patients and Methods section), exclusively on the
SNPs that passed the quality controls. A total of 1.6061010 two-
locus combinations were finally obtained. After applying control
direction and tracking filters, this software yielded 5x105 two locus
strata. Although none of them reached the cut off p value
established at 3.12610212 some pairs reached values close to that
threshold (Table S2).
Phase II. Validation and meta-analysis
To test the best genetic associations observed in phase I, first,
those SNPs that were included in any of the best 157 two-locus
signals (Table S2) were selected. These pairs accounted for 276
single SNPs because 38 SNPs were present in more than one pair.
Second, 79 SNPs from the single-locus analyses were selected
according to the association p value obtained in phase I (p,
6.961024) or the probability to be successfully genotyped with the
Veracode technology. Thus, a total of 355 SNPs were initially
selected for the preparation of custom-made arrays. However, it
was only possible to design oligonucleotide pools for 340 SNPs (79
single locus SNPs and 261 two-locus SNPs).
These genetic markers were genotyped in 423 different cases
and 1448 different controls (NXC-VAL sample). Age at recruit-
ment was 58.767.3 years in cases and 51.1612.9 in controls
(mean 6 standard deviation). The corresponding number
(percentage) of female samples was 262 (61.8%), and 920
(63.5%), respectively. Twenty SNPs did not pass the quality
control (14 SNPs were not genotyped in more than 80% of
samples, and 6 SNPs showed a HWE p-value ,0.001 in controls).
As for the samples, 66 controls were excluded (31 individuals did
not achieve a genotyping call rate .80%, and 35 individuals
showed some degree of relatedness to each other according to data
obtained with the GRR software). Finally 423 CRC cases and
1382 controls were genotyped with 320 markers (77 single-locus
and 243 two-locus selected SNPs) (Table S3). Table 1 shows those
selected SNPs that were replicated in the NXC-VAL sample (p,
0.05 and same effect direction). Only one SNP, rs3987 at 4q26,
reached a GWAS significant p-value in the meta-analysis (Table 2).
Interestingly, four more SNPs in the same genomic region showed
a trend for association at GWAS-significant p-value (Table 2).
Regarding two locus analysis, only five pairs were validated in
phase II (p,0.05 and same effect direction). Although none of
them reached GWAS significant p-value (p,3.12610212) in the
meta-analysis (Table 3), a SNP pair, rs1100508 CG and
rs8111948 AA, was borderline for association (4.35610211).
Result validation using additional datasets
To test whether the results could be replicated in another
Spanish dataset, we used data from the Epicolon project [23].
However, none of the SNPs that were considered significant or
candidates in phase II of this study replicated in this Epicolon
sample.
The results obtained in our GWAS (phase I and II), and those
obtained from the Epicolon cohort, were combined in an effort to
see a global effect of all those SNPs checked in phase II. None of
the SNPs reached the GWAS significant p-value in the combined
study (Table S4). Table 4 shows the best results obtained in this
study (selected from those SNPs showing an effect in the same
direction in all three analyzed series. See details from those
selected SNPs in Table S5).
Regarding two-locus HFCC analysis, no SNP-pair showed a
significant and consistent effect (in the same direction) when the 3
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samples (NXC-GWAS, NXC-Val and Epicolon) were analyzed
together.
Analysis of SNPs previously associated with CRC
Only one of the previously associated SNPs with CRC risk was
successfully genotyped in our GWAS. In order to cover a greater
number of these SNPs we imputed genotypes using CEU HapMap
data base and Plink software. After imputation, we obtained a total
of 1,371,009 SNPs for subsequent analysis. A total of 16 previously
reported as CRC associated SNPs were available at the time of the
analysis (Table 5). Of these, five SNPs located at 3q36.2
(rs10936599), 8q24 (rs10505477), 8q24.21(rs6983267), 11q13.4
(rs3824999) and 14q22.2 (rs4444235), showed nominal association
with CRC in our GWAS, and with effects in the same direction
than those previously reported (Table 5). Two more SNPs located
at 8q23.3 (rs16892766) and 12q13.13 (rs7136702) showed a trend
to nominal association with CRC in our study, again with the
effect in the same direction than previously reported (Table 5).
We could not test the candidate SNPs reported by Fernandez-
Rozadilla et al. [23] in their CRC-GWAS performed in the
Spanish population (Epicolon sample), because those candidates
were not covered or successfully genotyped/imputed in our study.
We also tested two-locus interactions between rs1571218
(20p12.3) and rs10879357 (12q21.1) previously associated with
CRC [21]. Applying general lineal models we did not observe any
evidence of interaction between them in our dataset (data not
shown).
Discussion
We present a new two-phase CRC-GWAS carried out in the
Spanish population for single locus and also for two-locus
association using our HFCC software [18]. One marker, rs3987
at 4q26, reached association with CRC susceptibility at GWAS
significant p-value. Furthermore, one SNP pair, rs1100508 CG
rs8111948 AA (located at 7q31.33 and 19q12, respectively),
showed also a trend for epistatic association.
In spite of limitations of our GWAS - low density of genomic
coverage of the DNA-chip, and a moderate sample size - we
replicated 5 of the 16 SNPs previously associated with CRC. In
addition, the majority of these 16 SNPs in our GWAS study were
in the same direction than in the published reports (Table 5).
Furthermore, regression analysis showed good concordance of the
odds ratios (Figure S3). These data together suggest that our study
is in line with previously published CRC GWAS analyses.
In our two-phase CRC-GWAS, one marker, namely rs3987 at
4q26, exhibited association with CRC susceptibility at GWAS
significant p-value. This SNP is located in an intergenic region of
4q26 between TRAM1L1 and NDST3 genes (,500 kb and
,180 kb, respectively). Several studies have already suggested
the presence of cancer genes in 4q region [24,25], and it has also
been reported that somatic deletions at 4q26 are frequent in CRC
[26,27]. Interestingly, the NDST4 gene, located also at 4q26, and
belonging to the same family than NDST3, has been identified as a
possible tumour suppressor gene in CRC [27].
The two-locus analysis revealed that one of the SNPs pairs,
rs1100508 CG and rs8111948 AA (located at 7q31.33 and 19q12,
respectively), showed a trend for association. These SNPs are in
intergenic regions located at 7q31.33 and 19q12. The closest gene
to rs1100508 is GPR37, a member of the G protein-coupled
receptor family that is known to interact with Parkin, albeit its
function remains to be fully characterized. On the other hand,
rs8111948 is located between LINC00662 and LINC00906
(,500 kb and ,600 kb, respectively), two loci belonging to the
long non-coding RNA (lncRNA) family. If the association of this
SNP pair is confirmed, the nature of that interaction will need to
be further characterized.
Figure 1. Manhattan plot of CRC-GWAS. Blue and red horizontal lines correspond to p values of 6.9761024 and 561028 respectively.
doi:10.1371/journal.pone.0101178.g001
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We also studied the markers associated with CRC from our
two-phase GWAS in an independent Spanish GWAS dataset
(Epicolon), but none of these associations replicated. However,
since our GWAS could validate more of the well-stablished CRC
associations than the Epicolon GWAS [23], we consider that the
candidates derived from our study deserve to be validated in
further meta-analysis including other GWAS and validation
studies performed in the Spanish population, or in a more general
Caucasian population.
According to the GWAS catalogue from NIH (http://www.
genome.gov/26525384), and previous works in this topic [5–15],
neither the variants associated with CRC reported in table 1 or 2,
nor variants included in the SNP pairs reported in table 3 (or in
linkage disequilibrium with them) have been previously associated
with CRC. Since the majority of these previous studies were not
particularly performed in the Southern Caucasian population, our
results could be specific for that population. An alternative
explanation would be that they are false positive. The clustering of
several SNPs at the same 4q26, and the replication of previously
reported associations argues against this possibility.
Although our results could not be replicated in the independent
Epicolon sample, we carried out a meta-analysis taking into
account the three samples analyzed here (NXC-GWAS, NXC-
VAL, and Epicolon). None of the SNPs, or combinations of them,
were replicated in the three samples, but the best signals comprise
several SNPs in linkage disequilibrium at 9q31.1, within or close to
LINC00587 locus (Table 4). This gene also belongs to the lncRNA
family involved in cellular differentiation and proliferation as post-
transcriptional regulators of splicing or as molecular decoys for
miRNA [28,29]. The expression of lncRNAs is deregulated in
many different cancers, including colon cancer [30], and some
studies suggest a role in cancer initiation, progression and
metastasis [31]. The association reported in previous GWAS
between CRC susceptibility and SNPs located at 8q24 could be
due to the PRNCR1 locus, a lncRNA member [32].
Interestingly, a high proportion of SNPs found to be associated
with CRC in our study discovery phase (tables 1, 2 and 4), were
selected by the two-locus analysis. This suggests that in addition to
identify epistatic interactions, our two-locus analysis method
(HFCC software) can also improve the capture of single signals
in the genome related to CRC susceptibility in particular and thus
in multigenic disease in general. This is an enticing hypothesis that
might be confirmed if some of these SNPs are validated in future
studies. On the other hand, the results of our two-locus analyses
suggest that the interaction signals have no more powerful
predictive value than single loci for CRC susceptibility because
of the failure to detect SNP pairs associated with CRC at GWAS
significant p-value. This observation, together with the absence of
statistically significant results in our global meta-analysis, as well as
the lack of replication of the only SNP pair interaction previously
reported as associated with CRC [21] suggests that the role of
genetic factors in CRC susceptibility might be more intricate that
previously thought.
In conclusion, we have carried out a CRC-GWAS in the
Spanish population that is in line with some previously reported
associations and yielded a new candidate SNP for CRC
susceptibility at 4q26 that needs to be validated in future studies.
Our two-locus study also provides evidence of the high level of
complexity in genetic cancer risk.
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Materials and Methods
Patients
Subjects in phase I were 801 controls from the Spanish general
population (which were previously described [33]) and 500 cases
diagnosed of CRC with pathological confirmation (NXC-GWAS
sample). In phase II 1448 controls and 423 cases of CRC were
used (NXC-VAL sample). CRC samples were collected in two
different Spanish hospitals (Hospital Universitario Virgen del
Rocı´o in Seville and Hospital Universitario 12 de Octubre in
Madrid) from November 2002 to April 2008. The control samples
included in phase II were collected during the same time period in
several primary health care centres from all around Spain. These
samples have been previously used as controls in other association
studies performed for different diseases in the Spanish population
[34]. Therefore, a total of 923 CRC cases and 2249 controls from
the Spanish general population were included in this study. All
individuals enrolled were Caucasian with registered Spanish
ancestors (two generations) as recorded by clinical researchers.
Ethics Statement
The ethics committees from Hospital Universitario Virgen del
Rocı´o, Sevilla, and Hospital Universitario 12 de Octubre, Madrid,
as well as Neocodex approved the research protocol, which was in
compliance with national legislation and performed according to
the ethical guidelines of the Declaration of Helsinki [35]. Written
informed consent was obtained from all individuals included in
this work.
External genotyping dataset
Genotyping data of selected SNPs from other GWAS
performed in the Spanish population (Epicolon cohort) [23] were
used as a reference for the results obtained herein. Specifically, this
cohort consisted in 882 cases and 473 controls ascertained through
the Epicolon II project and 194 additional controls from the
Spanish National DNA bank.
Genotyping
Peripheral blood from all cases and controls were used to isolate
germline DNA from leukocytes. DNA extraction was performed
automatically according to standard procedures using the
Magnapure DNA isolation system (Roche Diagnostics, Mann-
heim, Germany).
For genome-wide genotyping we used the Afymetrix NspI chip
as previously described [33]. For genotyping of selected SNPs in
the NXC-VAL sample we employed custom Golden Gate
protocols and Veracode genotyping assay (Illumina, San Diego,
California USA) according to the manufacturer’s instructions.
Data availability
Association results for genotyped and imputed SNPs are
provided as compressed Plink files (Dataset S1 and Dataset S2).
Case by case genotype data is available on request to the ethics
committee of the IMPPC (Instituto de Medicina Predictiva y
Personalizada del Ca´ncer) according to the conditions established
in the Spanish Law for Biomedical Research (Ley 14/2007, de 3
de julio).
Quality control analyses
For samples genotyped using the Affymetrix platform, we
performed an extensive quality control using Affymetrix Geno-
typing Console Software (http://www.affymetrix.com) and Plink
[22]. Only individuals with a sample call rate above 93% were
later re-called with the Bayesian Robust Linear Model with
Malalanobis (BRLMM) distance algorithm, ran with default
parameters. BRLLM improved call rates in most samples. Self-
reported sex was compared to sex assigned by chromosome X
genotypes, and discrepancies were resolved or samples removed.
The program Graphical Representation of Relationships (GRR)
[36] was used to check sample relatedness and to correct potential
sample mislabelling, duplications, or contaminations. SNPs were
selected to have a call rate above 95% (in each case, control, and
combined group), and a minor allele frequency above 1% (again in
each case, control, and combined group). SNPs that deviated
grossly from Hardy-Weinberg equilibrium (HWE) (P-value ,
1024) in control samples were also removed. We also removed
SNPs with a significantly different rate of missingness (P-value ,
561024) between case and control samples.
Similarly, SNPs genotyped in the phase II were subjected to
quality control filters. Thus, those SNPs that were not successfully
genotyped in at least 80% of individuals, and those with a p-value
for Hardy–Weinberg equilibrium (HWE) lower than 0.001 were
discarded. In addition, individuals with more than 10% of missing
genotype data or that showed relatedness to each other were also
excluded.
Principal components analysis
Principal component analysis was carried out with EIGEN-
SOFT [37,38] to evaluate population admixture within our
population, and to identify individuals as outliers. We ran the
SMARTPCA program with default parameters, excluding chro-
mosome X markers and using independent SNPs (pairwise r2,
0.1). To minimize the effect of linkage disequilibrium in the
analysis, long-range linkage disequilibrium regions previously
reported [39] or detected in our population were also excluded.
Individuals identified as outliers (six standard deviations or more
along one of the top ten principal components) were removed
from all subsequent analyses. Principal component analysis was
run together with other HapMap European and worldwide
populations to detect individuals of different ethnicities.
Single locus association analysis
Unadjusted single-locus allelic (1 degree of freedom, df)
association analyses were carried out using Plink software [22],
independently within each group of subjects from phase I or phase
II. Meta-analysis tool in Plink was used to analyze combined data
from different datasets. In these studies, fixed effects models were
employed when no evidence of heterogeneity was found.
Otherwise random effects models were employed. A GWAS
significant p-value was established at 561028 [40]. Plink was also
employed to estimate the genomic inflation factor. Haploview
software [41] was employed for graphical representation of the
GWAS single locus analysis results (Manhattan plot). The
concordance of the detected effect and the reported effect for
those SNPs previously found to be associated with CRC was
analyzed by linear regression after logarithmic transformation of
the odds ratios.
Two-locus association analysis
Aiming to detect potential epistatic loci, we explored the entire
universe of two-locus interactions (all SNP x SNP interactions)
using the Hypothesis Free Clinical Cloning (HFCC) software as
described previously [18]. Briefly, in phase I three different
replication groups of 160 cases and 267 controls were created. In
order to be considered a preliminary positive result, the chi-square
(1 df) test cut-off value was set at 6.64 (p,0.01) and the direction
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of the effect had to be the same for each replication group (which
approximates to p,161026 over all three replication groups).
To explore the nature and strength of interactions in selected
two-locus patterns, we further evaluated epistasis among selected
markers using Alambique software [18]. Specifically, Alambique
was programmed to measure departure from additive models by
calculating the Synergy index, AP or RERI statistics, whilst
departure from multiplicity was measured by computing strata-
specific odds ratios and case-only interaction test. The algorithms
included in the Alambique software have been previously
described elsewhere [42,43].
During the validation process, those SNPs selected by HFCC
that were successfully genotyped in the NXC-VAL sample were
analyzed for replication. In this case two groups of replication were
created: the NXC-GWAS sample and the NXC-VAL sample.
When the selected pairs were also studied in the Epicolon cohort,
three groups of replication were created: NXC-GWAS, NXC-
VAL and the Epicolon sample.
Multiple-testing correction was applied in those studies taking
into account the number of different SNP-pairs generated. Thus,
the p-value threshold was established at (p = 3.12610212 (0.05/
total number of SNP-pairs generated in the phase I dataset).
To test the two-locus interaction that was previously associated
with CRC susceptibility [21], i.e. rs1571218 (20p12.3) and
rs10879357 (12q21.1), we modelled the interaction using linear
regression with SPSS software 19.0 (IBM Corporation, Somers,
NY, USA).
Imputation
We imputed genotypes using HapMap phase 2 CEU founders
(n = 60) as a reference panel with Plink [22]. Genotype calls with
high quality scores (info.0.8) were used in subsequent association
analyses.
Supporting Information
Figure S1 Scatterplot of the two main eigenvectors
obtained from the principal component analysis per-
formed on 801 controls (green circles) and 480 cases
(blue circles) selected for the phase-I association study.
(PDF)
Figure S2 Quantile-Quantile (Q-Q) plot of the observed
and expected x2 values obtained from the study of the
association between SNP genotype and colorectal cancer
risk.
(PDF)
Figure S3 Correlation between the effects (OR) found in
the NXC-GWAS and the reported effects for the 16 SNPs
previously found to associate with CRC risk. The blue line
represents perfect correlation. The green line indicates the
correlation excluding the outlayer rs16969681 (red circle). This
SNP was originally reported in the UK2 GWAS with an OR of
1.247, that reached GWAS significant after meta analysis with
other Northern Europe GWAS but was not replicated in the
Epicolon GWAS of Southern Europe. The coefficient of
determination (R2) and p-value (Pearson’s P) of the correlation
are indicated. Without excluding the rs16969681, the coefficient of
determination and p-value were 0.28 and 0.035, respectively.
(PDF)
Table S1 Best phase I results obtained by Plink.
(DOC)
Table S2 Best SNP6SNP interactions obtained by HFCC
software.
(DOC)
Table S3 SNPs included in the phase II and meta-
analysis results.
(DOC)
Table S4 SNPs included in the stage II and global meta-
analysis results.
(DOC)
Table S5 Details of the results obtained in each sample
from those SNPs that showed the best results in the
global meta-analysis.
(DOC)
Dataset S1 Plink association file of genotyped SNPs.
(ZIP)
Dataset S2 Plink association file of imputed SNPs.
(ZIP)
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